The antitumoral profile of the microtubule disrupter
N
-(4-iodophenyl)-
N
′-(2-chloroethyl)urea (ICEU) was characterised
in vitro
and
in vivo
using the CT-26 colon carcinoma cell line, on the basis of the drug uptake by the cells, the modifications of cell cycle, and
β
-tubulin and lipid membrane profiles.
N
-(4-iodophenyl)-
N
′-(2-chloroethyl)urea exhibited a rapid and dose-dependent uptake by CT-26 cells suggesting its passive diffusion through the membranes. Intraperitoneally injected ICEU biodistributed into the grafted CT-26 tumour, resulting thus in a significant tumour growth inhibition (TGI).
N
-(4-iodophenyl)-
N
′-(2-chloroethyl)urea was also observed to accumulate within colon tissue. Tumour growth inhibition was associated with a slight increase in the number of G2 tetraploid tumour cells
in vivo
, whereas G2 blockage was more obvious
in vitro.
The phenotype of
β
-tubulin alkylation that was clearly demonstrated
in vitro
was undetectable
in vivo
. Nuclear magnetic resonance analysis showed that cells blocked in G2 phase underwent apoptosis, as confirmed by an increase in the methylene group resonance of mobile lipids, parallel to sub-G1 accumulation of the cells.
In vivo
, a decrease of the signals of both the phospholipid precursors and the products of membrane degradation occurred concomitantly with TGI. This multi-analysis established, at least partly, the ICEU activity profile,
in vitro and in vivo
, providing additional data in favour of ICEU as a tubulin-interacting drug accumulating within the intestinal tract. This may provide a starting point for researches for future efficacious tubulin-interacting drugs for the treatment of colorectal cancers.